| Population 2017 |
105 million |
| |
| | | | | |
| Estimates of TB burden*, 2017 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
26 |
(23–31) |
25 |
(22–29) |
| Mortality (HIV+TB only) |
0.38 |
(0–3.3) |
0.36 |
(0–3.1) |
| Incidence (includes HIV+TB) |
581 |
(326–909) |
554 |
(311–866) |
| Incidence (HIV+TB only) |
7.1 |
(2.9–13) |
6.7 |
(2.8–12) |
| Incidence (MDR/RR-TB)** |
27 |
(12–47) |
26 |
(12–45) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2017 |
| |
0-14 years |
> 14 years |
Total |
| Females |
34 |
(30–38) |
139 |
(105–173) |
173 |
(126–220) |
| Males |
37 |
(33–42) |
371 |
(223–519) |
408 |
(237–580) |
| Total |
71 |
(59–84) |
510 |
(271–749) |
581 |
(326–909) |
| |
| | | | | |
| TB case notifications, 2017 |
|
| Total cases notified |
328 773 |
| Total new and relapse |
317 266 |
| - % tested with rapid diagnostics at time of diagnosis |
26% |
| - % with known HIV status |
24% |
| - % pulmonary |
98% |
| - % bacteriologically confirmed among pulmonary |
39% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2017 |
55% (35–97) |
| TB patients facing catastrophic total costs, 2017 |
35% |
| TB case fatality ratio (estimated mortality/estimated incidence), 2017 |
0.05 (0.03–0.08) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2017 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
1 335 |
2% |
| - on antiretroviral therapy |
1 185 |
89% |
| |
| | | | | |
| Drug-resistant TB care, 2017 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
20 000
(18 000–22 000) |
| Estimated % of TB cases with MDR/RR-TB |
2.6% (1.9–3.4) |
28% (27–28) |
|
| % notified tested for rifampicin resistance |
19% |
83% |
93 058 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
2 401 |
| Laboratory-confirmed cases |
MDR/RR-TB: 6 438, XDR-TB: 15 |
| Patients started on treatment **** |
MDR/RR-TB: 5 623, XDR-TB: 16 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2016 |
91% |
332 308 |
| Previously treated cases, excluding relapse, registered in 2016 |
80% |
10 097 |
| HIV-positive TB cases registered in 2016 |
82% |
989 |
| MDR/RR-TB cases started on second-line treatment in 2015 |
54% |
3 851 |
| XDR-TB cases started on second-line treatment in 2015 |
33% |
9 |
| |
| | | | | |
| TB preventive treatment, 2017 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
57% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
12% (11–13) |
| |
| | | | | |
| TB financing, 2018 |
|
| National TB budget (US$ millions) |
160 |
| Funding source: 37% domestic, 21% international, 42% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed | | |
| | | | | |